The Developmental Processes in Schizophrenic Disorders project involves an ongoing series of longitudinal studies of the psychopathology and treatment of individuals with a recent onset of schizophrenia. The proposed new protocol focuses on improving the efficacy of interventions targeting work and school functioning during the early stage of schizophrenia and examining the mediators of their effects. Effective interventions for individuals in the early stage of schizophrenia are critical for preventing chronic patterns of disability and are therefore of particular public health significance. The new protocol aims to build upon the substantial gains in work and school re-entry that were achieved with the current treatment protocol using Individual Placement and Support and Workplace Fundamental Modules. Based on evidence that neurocognitive deficits and medication non-adherence are key determinants of impaired work performance, the new protocol will test whether cognitive remediation procedures, aimed at improving neurocogriition, and injectable, long-acting risperidone, aimed at increasing medication adherence, can increase work/school performance. Hypothesized mechanisms through which these treatments may influence functional outcome will be evaluated. To clarify the mediators and moderators of the impact of cognitive remediation on work/school functioning, aspects of social cognition, coping skills, learning of work skills, awareness of illness, and motivation will be examined. The study will determine whether injectable, long-acting risperidone improves medication adherence, clinical course, and work/school functioning as compared to oral risperidone. Potential predictors of response to these treatments will be evaluated. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
5R01MH037705-21
Application #
7156192
Study Section
Special Emphasis Panel (ZMH1-ERB-D (06))
Program Officer
Heinssen, Robert K
Project Start
1983-09-15
Project End
2010-11-30
Budget Start
2006-12-01
Budget End
2007-11-30
Support Year
21
Fiscal Year
2007
Total Cost
$575,429
Indirect Cost
Name
University of California Los Angeles
Department
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Chen, Qiaolin; Sugar, Catherine A; Weiss, Robert E (2018) A Bayesian confirmatory factor model for multivariate observations in the form of two-way tables of data. Stat Med 37:1696-1710
Fernandez, Vindia G; Asarnow, Robert; Narr, Katherine L et al. (2018) Temporal lobe thickness and verbal memory in first-degree relatives of individuals with schizophrenia. Schizophr Res 199:221-225
Rosenfarb, Irwin Ford; Triana, Stephanie; Nuechterlein, Keith H et al. (2017) Expressed emotion and the escalation of depressive symptoms in individuals with recent-onset schizophrenia. Early Interv Psychiatry 11:351-353
McCleery, Amanda; Lee, Junghee; Fiske, Alan P et al. (2016) Longitudinal stability of social cognition in schizophrenia: A 5-year follow-up of social perception and emotion processing. Schizophr Res 176:467-472
Ventura, Joseph; Subotnik, Kenneth L; Ered, Arielle et al. (2016) Cognitive Assessment Interview (CAI): Validity as a co-primary measure of cognition across phases of schizophrenia. Schizophr Res 172:137-42
Nuechterlein, Keith H; Ventura, Joseph; McEwen, Sarah C et al. (2016) Enhancing Cognitive Training Through Aerobic Exercise After a First Schizophrenia Episode: Theoretical Conception and Pilot Study. Schizophr Bull 42 Suppl 1:S44-52
Ventura, J; Ered, A; Gretchen-Doorly, D et al. (2015) Theory of mind in the early course of schizophrenia: stability, symptom and neurocognitive correlates, and relationship with functioning. Psychol Med 45:2031-43
Pirnia, Tara; Woods, Roger P; Hamilton, Liberty S et al. (2015) Hippocampal dysfunction during declarative memory encoding in schizophrenia and effects of genetic liability. Schizophr Res 161:357-66
Subotnik, Kenneth L; Casaus, Laurie R; Ventura, Joseph et al. (2015) Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial. JAMA Psychiatry 72:822-9
McCleery, A; Green, M F; Hellemann, G S et al. (2015) Latent structure of cognition in schizophrenia: a confirmatory factor analysis of the MATRICS Consensus Cognitive Battery (MCCB). Psychol Med 45:2657-66

Showing the most recent 10 out of 135 publications